Journal Mobile Options
Table of Contents
Vol. 12, No. 3, 2005
Issue release date: May 2005
Section title: Original Paper
Neuroimmunomodulation 2005;12:157–163
(DOI:10.1159/000084848)

Human Endometrial Leukemia Inhibitory Factor and Interleukin-6: Control of Secretion by Transforming Growth Factor-β-Related Members

Perrier d’Hauterive S. · Charlet-Renard C. · Dubois M. · Berndt S. · Goffin F. · Foidart J.-M. · Geenen V.
aUniversity of Liège, Department of Medicine, Center of Immunology, Institute of Pathology CHU-B23, Liège-Sart Tilman, bUniversity of Liège, Department of Gynecology and Obstetrics, CHR-Citadelle, Liège, and cUniversity of Liège, Institute of Pathology CHU-B23, Laboratory of Tumor and Developmental Biology, Liège-Sart Tilman, Belgium

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/16/2003
Accepted: 8/11/2004
Published online: 5/17/2005

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: http://www.karger.com/NIM

Abstract

Objective(s): The implantation process is closely linked to the fundamental question of the tolerance of the maternal immune system. The main objective of this study was to investigate whether different members of the transforming growth factor-β (TGF-β) superfamily could intervene in the first steps of embryo implantation by modulating the secretion of proimplantatory leukemia inhibitory factor (LIF) and in the tolerance of the fetal graft by regulating proinflammatory interleukin (IL)-6 secretion by human endometrial epithelium (EEC) in vitro. Methods: EEC were isolated from biopsies collected from 16 informed and consenting fertile women and were cultured for 72 h. Cytokine measurements (LIF and IL-6) were realized by ELISA. Results: TGF-β1 (from 10–12 to 10–8M), -β2, -β3 and activin A (10–10 and 10–8M) increased LIF secretion by EEC cultures. Inhibin B (10–10 and 10–8M) did not stimulate LIF production by human EEC. Contrastingly, TGF-β1 (from 10–12 to 10–8M), -β2, -β3 and activin A (10–10 and 10–8M) reduced IL-6 release by the same cells. Activin A at 10–8 M also significantly reduced the stimulating effect of IL-1β (10–9M) which is known to stimulate LIF production by EEC. Only the highest concentration of inhibin B (10–8M) reduced IL-6 secretion by EEC, but did not modulate IL-1β-induced stimulation of IL-6 secretion. Conclusion(s): Besides their role in the control of the process of implantation and in the induction of embryonic mesoderm, different members of the TGF-β superfamily may also contribute in the reproductive process by enhancing endometrial proimplantatory LIF secretion and reducing proinflammatory IL-6 release by EEC.


  

Author Contacts

Sophie Perrier d’Hauterive, MD, PhD
University of Liège, Department of Gynecology and Obstetrics
Center of Immunology, Institute of Pathology CHU-B23
BE–4000 Liège-Sart Tilman (Belgium)
Tel. +32 4 3662537, Fax +32 4 3662977, E-Mail sperrier@ulg.ac.be

  

Article Information

Received: April 16, 2003
Accepted after revision: August 11, 2004
Number of Print Pages : 7
Number of Figures : 3, Number of Tables : 0, Number of References : 44

  

Publication Details

Neuroimmunomodulation

Vol. 12, No. 3, Year 2005 (Cover Date: Released May 2005)

Journal Editor: Chrousos, G.P. (Bethesda, Md.)
ISSN: 1021–7401 (print), 1423–0216 (Online)

For additional information: http://www.karger.com/nim


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 4/16/2003
Accepted: 8/11/2004
Published online: 5/17/2005

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: http://www.karger.com/NIM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.